OptiBiotix Health Plc., a leading life sciences company focused on harnessing the power of human microbiome modulation to tackle obesity, high cholesterol and diabetes, has entered into a five-year agreement with India’s leading contract manufacturer Akums Drugs and Pharmaceuticals Ltd.
The agreement, signed at VitaFoods Europe, held in Geneva, 15-17 May, grants Akums the rights to exclusively manufacture and supply products containing OptiBiotix’s next-generation probiotic strain for cardiovascular health, LPLDL®, in India. This is a strategic step to add manufacturing to the supply chain in the Asian probiotic supplements and pharmaceuticals markets and extends the commercial reach of LPLDL® into Southern Asia.
Stephen O’Hara, OptiBiotix CEO, said: “We are very excited to announce this agreement with Akums, which will extend access to our leading-edge probiotic product LPLDL®. This means OptiBiotix will be able to offer multiple product solutions to consumer health and pharmaceutical companies across the Asian region.
“Akums is the largest contract manufacturing company in India for food supplements and pharmaceuticals and we were impressed with their extensive experience in manufacturing products for many well-known global food and pharmaceutical organisations. This exciting partnership will combine OptiBiotix’s expertise in microbiome modulation with Akum’s manufacturing capacity and scale to deliver the real, measurable health benefits of LPLDL® to the Asian marketplace.”
LPLDL® is OptiBiotix’s revolutionary next-generation probiotic product which uses a naturally occurring bacterial strain, Lactobacillus plantarum, to reduce cholesterol and aid management of other cardiovascular biomarkers including high blood pressure. Independent human studies have shown LPLDL® to be safe and effective and able to reduce LDL, total cholesterol and blood pressure.
Akums is the largest contract manufacturing organisation in India and is the manufacturing partner of choice for more than 600 companies in the pharmaceutical and food supplement markets. The company offers more than 3,500 formulations across key health areas, including cardiovascular disease, supplying more than 12% of all food and drug supplements consumed in India.
For more information about Optibiotix, please visit www.optibiotix.com